Metacrine Choosing Between Two NASH FXR Agonists It Calls Best-In-Class

 
• By Joseph Haas
  
Scales_140867215_1200.jpg
Metacrine is evaluating two FXR agonists to determine which to advance in NASH
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D